A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

-Men or women > 18 years old -Pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or which no standard therapy is available, or the subject refuses standard therapy or multiple myeloma -Willing to undergo pre-dose core needle tumor biopsies or bone marrow aspirate for subjects with multiple myeloma. -Ability to take oral medications and willing to record daily adherance to investigational product -Adequate hematological, renal, hepatic, and coagulation laboratory assessments

-Active brain metastases -For solid tumor-History or presence of hematological malignancies unless curatively treated with no evidence of disease for greater than or equal to 5 years -Active infection requiring intravenous (IV) antibiotics -Anti-tumor therapy -Therapeutic or palliative radiation therapy within 30 days of starting treatment -Currently enrolled in another investigational device or drug study